Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:30 PM
Ignite Modification Date:
2025-12-24 @ 4:30 PM
NCT ID:
NCT07154966
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed diagnosis of non-metastatic ovarian, fallopian tube, or endometrial cancer
* Planned to receive adjuvant or neoadjuvant carboplatin-paclitaxel regimen (carboplatin AUC 5 + paclitaxel 175-200 mg/m² every 21 days)
* No prior chemotherapy
* Age ≥ 18 years, female
* Completion of 6 cycles of carboplatin-paclitaxel treatment
* Availability of CT imaging at baseline, after third cycle, and after sixth cycle
* Ability to provide written informed consent
Exclusion Criteria:
* Metastatic disease or palliative treatment setting
* Treatment with regimens other than carboplatin-paclitaxel or weekly protocols
* Prior systemic therapy (e.g., immunotherapy, targeted therapy) Initial treatment discontinuation due to progression, toxicity, or patient preference
* Missing CT imaging at required timepoints
* Pregnancy or breastfeeding
* Cognitive impairment or inability to provide informed consent
* Severe comorbid conditions (e.g., uncontrolled cardiac disease, end-stage renal failure, advanced liver failure)
* Inability to comply with study assessments or follow-up visits
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT07154966
Study Brief:
Protocol Section:
NCT07154966